Welcome to our dedicated page for Quanterix SEC filings (Ticker: QTRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Quanterix Corporation (NASDAQ: QTRX) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, along with AI‑supported context to help interpret them. As a life sciences and testing laboratories company focused on ultra-sensitive biomarker detection and spatial biology, Quanterix uses its SEC reports to describe its financial performance, corporate transactions, and governance decisions.
Key documents available here include Form 10‑K annual reports and Form 10‑Q quarterly reports, which outline revenue from product sales, service and other revenue, collaboration and license revenue, and grant revenue. These filings also discuss cost of goods sold, research and development expenses, selling, general and administrative expenses, and the use of non‑GAAP measures such as adjusted EBITDA, adjusted gross margin, and adjusted cash usage. AI summaries can highlight how these metrics relate to Quanterix’s Simoa platforms, Accelerator Laboratory services, and the integration of Akoya Biosciences.
Frequent Form 8‑K current reports document material events. Recent examples include announcements of quarterly financial results, the completion and pro forma impact of the Akoya acquisition, shareholder votes on declassifying the Board and eliminating supermajority voting requirements, and changes in Board composition. Our tools surface the main points of each 8‑K so readers can quickly understand what changed and why it matters for QTRX.
Investors can also review proxy statements referenced in the filings for details on director elections, executive compensation proposals, and governance changes, as well as any Form 4 insider transaction reports that may be filed separately. Real‑time updates from EDGAR ensure that new filings appear promptly, while AI‑generated explanations help translate technical accounting and legal language into more accessible summaries.
Use this page to explore Quanterix’s historical and current SEC filings, compare reporting periods, and understand how financial results, acquisitions, and governance actions are reflected in official disclosures.
Quanterix Corporation is holding its 2026 annual stockholder meeting virtually at 10:00 a.m. ET on June 9, 2026 via meetnow.global/QTRX2026. Holders of common stock as of April 14, 2026, when 47,064,988 shares were outstanding, may vote.
Stockholders will vote on electing two directors to one-year terms, an advisory approval of named executive officer compensation, an advisory ratification of KPMG LLP as independent auditor for 2026, and approval of an amended and restated 2017 Employee, Director and Consultant Equity Incentive Plan, plus any other properly presented business.
Quanterix Corp Chief Operating Officer Michael Francis Miller exercised restricted stock units into common stock and had shares withheld to cover taxes. On April 15, 2026, he acquired a total of 1,558 shares of common stock through multiple RSU conversions, all at a stated price of $0.00 per share.
To satisfy tax obligations related to these vesting events, 467 shares of common stock were disposed of at $3.60 per share in tax-withholding transactions. Following these transactions, Miller directly held 32,522 shares of Quanterix common stock.
Quanterix Corp Chief Financial Officer Sriram Vandana reported routine equity compensation activity involving restricted stock units that converted into common stock. On April 15, 2026, restricted stock units converted into common stock on a one-for-one basis, delivering 263, 514 and 1,056 shares in separate tranches.
Related common stock entries show 263, 514 and 1,056-share acquisitions at a price of $0.00 per share. To satisfy tax obligations, 79, 154 and 315 shares of common stock were withheld at $3.60 per share as tax-withholding dispositions, rather than open-market sales.
Following these transactions, the filing shows Sriram Vandana directly holding 28,713 shares of Quanterix common stock. The derivative section lists no remaining restricted stock units tied to these specific conversions, underscoring that the reported activity reflects compensation vesting and associated tax withholding.
DONNELLY WILLIAM P reported acquisition or exercise transactions in this Form 4 filing.
Quanterix Corp Executive Chair William P. Donnelly received 6,178 shares of Common Stock as a stock grant. The shares were awarded at a stated price of $0.00 per share as a grant or award transaction, rather than an open-market purchase or sale.
According to the disclosure, this stock was granted in lieu of cash fees for Donnelly’s service on Quanterix’s Board of Directors and its committees for the first quarter of 2026. Following this award, Donnelly directly holds a total of 154,127 shares of Quanterix Common Stock.
Mendel Scott reported acquisition or exercise transactions in this Form 4 filing.
Quanterix Corp director Scott Mendel received a grant of 4,310 shares of common stock as compensation. The shares were granted in lieu of cash fees for his service on the company’s Board of Directors and its committees for the first quarter of 2026. Following this award, he directly holds 12,527 shares.
Quanterix Corp Chief Operating Officer Michael Francis Miller exercised restricted stock units into common shares and had a portion withheld for taxes. On March 31, 2026, he converted 229 restricted stock units, which convert to common stock on a one-for-one basis, into the same number of common shares at a stated price of $0.00 per share.
To cover tax obligations, 69 common shares were disposed of through tax-withholding transactions at $3.52 per share, leaving him with a net increase of 160 common shares. Following these transactions, Miller directly owned 31,431 shares of Quanterix common stock. The restricted stock units exercised were part of prior grants from April 7, 2022 and September 23, 2022 that vest over time.
The Vanguard Group amended its Schedule 13G/A to report zero beneficial ownership of Quanterix Corp common stock. The filing (Amendment No. 2) explains an internal realignment effective January 12, 2026, after which certain Vanguard subsidiaries report holdings separately. The schedule states Amount beneficially owned: 0 and Percent of class: 0%. The amendment is signed by Ashley Grim on 03/27/2026.
Quanterix Corp Chief Legal Officer Daniel Char has reported initial equity holdings. The filing shows grants received on January 15, 2026 of 33,962 restricted stock units tied to common stock and 113,171 stock options to buy common shares at an exercise price of $7.95 per share. Both awards vest 25% on the first anniversary of the grant date, with the remaining 75% vesting in 36 equal monthly installments, creating a multi-year incentive structure aligned with continued service.
Quanterix Corp’s Chief Operating Officer Michael Francis Miller reported routine equity compensation activity. On March 15, 2026, multiple restricted stock unit awards converted into common stock, with derivative exercises totaling 1,558 shares according to the filing’s transaction summary.
To cover related tax obligations, 549 common shares were withheld at a price of $4.72 per share under code F transactions, which are tax-withholding dispositions rather than market sales. Following these transactions, Miller directly holds 31,271 shares of Quanterix common stock.